GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Telesis Bio Inc (NAS:TBIO) » Definitions » Sloan Ratio %

Telesis Bio (Telesis Bio) Sloan Ratio % : -10.39% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Telesis Bio Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Telesis Bio's Sloan Ratio for the quarter that ended in Dec. 2023 was -10.39%.

As of Dec. 2023, Telesis Bio has a Sloan Ratio of -10.39%, indicating there is a warning stage of accrual build up.


Telesis Bio Sloan Ratio % Historical Data

The historical data trend for Telesis Bio's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telesis Bio Sloan Ratio % Chart

Telesis Bio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
- -9.03 10.99 10.14 -10.39

Telesis Bio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.14 -38.28 -29.29 -3.95 -10.39

Competitive Comparison of Telesis Bio's Sloan Ratio %

For the Medical Devices subindustry, Telesis Bio's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telesis Bio's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Telesis Bio's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Telesis Bio's Sloan Ratio % falls into.



Telesis Bio Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Telesis Bio's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-47.724--34.667
--5.744)/70.411
=-10.39%

Telesis Bio's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(-47.724--34.667
--5.744)/70.411
=-10.39%

Telesis Bio's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -11.119 (Mar. 2023 ) + -8.287 (Jun. 2023 ) + -10.631 (Sep. 2023 ) + -17.687 (Dec. 2023 ) = $-47.72 Mil.
Telesis Bio's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was -11.167 (Mar. 2023 ) + -10.3 (Jun. 2023 ) + -5.888 (Sep. 2023 ) + -7.312 (Dec. 2023 ) = $-34.67 Mil.
Telesis Bio's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was 4.123 (Mar. 2023 ) + 6.846 (Jun. 2023 ) + -23.208 (Sep. 2023 ) + 6.495 (Dec. 2023 ) = $-5.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telesis Bio  (NAS:TBIO) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, Telesis Bio has a Sloan Ratio of -10.39%, indicating there is a warning stage of accrual build up.


Telesis Bio Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Telesis Bio's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Telesis Bio (Telesis Bio) Business Description

Traded in Other Exchanges
N/A
Address
10431 Wateridge Circle, Suite 150, San Diego, CA, USA, 92121
Telesis Bio Inc is a synthetic biology company focused on enabling researchers to rapidly, accurately, and reproducibly build or write high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology-enabled markets. It manufactures and sells laboratory equipment, specifically synthetic biology instruments, reagents, and associated products and related services. Its products comprise of BioXp system, BioXp kits, Benchtop reagents, Coronavirus tools, and BioXp biofoundry services.
Executives
Gregory J. Herrema director 355 RIVER OAKS PARKWAY, SAN JOSE CA 95134
Marijn E Dekkers 10 percent owner GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210
Novalis Lifesciences Investments Ii Gp, Llc 10 percent owner 1 LIBERTY LANE E, SUITE 112, HAMPTON NH 03842
Novalis Lifesciences Investments Ii, L.p. 10 percent owner 1 LIBERTY LANE E, SUITE 112, HAMPTON NH 03842
Broadoak Fund Iv, Llc 10 percent owner 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
William Snider director, 10 percent owner 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
Paul M Meister director, 10 percent owner 18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862
Rob Cutler officer: Chief Legal Officer C/O TELESIS BIO, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Daniel Glenn Gibson officer: Chief Technology Officer C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Todd Robert Nelson director, 10 percent owner, officer: President & CEO C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Eric Eugene Esser officer: Chief Operating Officer C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Annette Tumolo director C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Northpond Ventures Gp, Llc 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
Northpond Ventures Gp Ii, Llc 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BESTHESDA MD 20814
Northpond Ventures Ii, Lp 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814